Remitch (nalfurafine hydrochloride) OD tablets 2.5 mcg for pruritus (hemodialysis, chronic liver disease, antipruritic)

Are Remitch (nalfurafine hydrochloride) OD tablets 2.5 mcg effective for pruritus (hemodialysis, chronic liver disease, antipruritic treatment)?

Remitch tablets containing nalfurafine hydrochloride are a prescription antipruritic medicine developed in Japan for the treatment of severe, treatment-resistant pruritus. Chronic itching, particularly uremic pruritus in patients undergoing hemodialysis or pruritus associated with chronic liver disease, is not a minor complaint. It significantly disrupts sleep, emotional wellbeing, and daily functioning, and has been associated with increased mortality risk. Remitch tablets address this unmet clinical need through a targeted and scientifically validated pharmacological mechanism.

Targeted Mechanism for Persistent Itching

Nalfurafine hydrochloride, the active ingredient in Remitch, is a centrally acting κ-opioid receptor (KOR) agonist derived from structural modification of the opioid antagonist naltrexone. By selectively activating the KOR pathway, nalfurafine modulates itch transmission within the central nervous system, a level at which conventional antihistamines and topical treatments often fail to provide adequate relief.

A clinically important characteristic of Remitch is its pharmacological selectivity. Unlike earlier κ-opioid receptor agonists, nalfurafine does not produce hallucinogenic or psychotomimetic effects in humans, enabling effective antipruritic activity while maintaining tolerability during long-term use.

Proven Effectiveness in Hemodialysis-Associated Pruritus

The clinical efficacy of Remitch tablets is supported by robust evidence from large-scale studies conducted in Japan. In a randomized, placebo-controlled trial involving 337 hemodialysis patients with intractable pruritus, oral nalfurafine hydrochloride demonstrated a statistically significant reduction in itch severity compared with placebo.

According to S. Inui, “Nalfurafine hydrochloride to treat pruritus: a review,” Clinical, Cosmetic and Investigational Dermatology, 2015, Volume 8, pages 249–255, the mean reduction in visual analog scale scores for pruritus reached 22 mm in the 5 μg group and 23 mm in the 2.5 μg group, compared with 13 mm in the placebo group. These findings confirm clinically meaningful symptom relief in a population where pruritus is frequently refractory to standard therapies.

Key Benefits of Remitch Tablets

• Clinically proven reduction of severe, intractable pruritus
• Central mechanism of action targeting itch signaling beyond the skin
• High selectivity for κ-opioid receptors without hallucinogenic effects
• Developed and extensively studied in Japan for uremic pruritus
• Appropriate for patients with chronic itching unresponsive to conventional treatments

Role in Modern Pruritus Management

As a specialized antipruritic medicine, Remitch tablets occupy an important place in contemporary pruritus management, particularly for patients undergoing hemodialysis or those with chronic liver disease. Their unique mechanism of action distinguishes them from antihistamines, corticosteroids, and topical agents, offering an effective option when standard therapies fail to control symptoms.

Patients and healthcare professionals seeking to buy nalfurafine or select antipruritic therapies supported by strong clinical evidence often consider Remitch for its demonstrated efficacy, tolerability, and targeted pharmacology. For individuals affected by persistent, debilitating itch, Remitch represents a scientifically grounded approach to improving quality of life and overall clinical outcomes.

Package details: 14 tablets

Dosage and administration: Adults should take one Remitch OD tablet (2.5 mcg of nalfurafine hydrochloride) once daily after dinner or before bedtime. The dosage may be adjusted by a physician according to symptom severity, with a maximum daily dose of two tablets (5 mcg) at one time. When used for pruritus associated with hemodialysis, sufficient time should elapse between administration and the start of dialysis. When used for pruritus associated with peritoneal dialysis, adequate time should be allowed before dialysate exchange.

The tablet may be moistened with saliva on the tongue, gently crushed using the tongue, and swallowed together with saliva.

Active component: nalfurafine hydrochloride

Therapeutic effect: Improvement of pruritus in patients who have shown an inadequate response to conventional therapies, including those undergoing hemodialysis or with chronic liver disease

Contraindications and precautions: Store in a cool, dry place out of reach of children. Do not use during pregnancy or breastfeeding. This medicine may cause drowsiness or lightheadedness; avoid operating hazardous machinery, including driving. Do not consume grapefruit juice, as it may enhance the effects of the medicine. Avoid exposure to excessive heat or direct sunlight. If allergic symptoms occur, discontinue use and consult a healthcare professional.